Core Viewpoint - The current rotation within ARK Invest indicates a strong belief that 2026 will be a pivotal year for the genomic revolution [1] Group 1: Investment Strategy - ARK Invest is significantly reducing its holdings in legacy winners like Tesla and Rocket Lab to invest millions in gene-editing companies [2] - The firm is focusing on acquiring shares of CRISPR Therapeutics, Intellia Therapeutics, Beam Therapeutics, and Pacific Biosciences as 2025 ends [3] Group 2: Thematic Focus - Cathie Wood's investment thesis combines artificial intelligence with programmable biology, emphasizing AI's transformative potential in healthcare [4] - The multiomics flywheel framework suggests that AI enhances all aspects of multiomics, from biological data generation to disease diagnosis and drug development [4] Group 3: Technological Advancements - Improved algorithms are making gene sequencing faster, while cheaper sequencing provides more data for AI learning, leading to breakthroughs in gene editing and new treatment possibilities [5] Group 4: Holdings Overview - By late December 2025, ARK increased its stake in CRISPR Therapeutics to over 5% of the ARKK Innovation Fund, with Beam Therapeutics at 3.41%, Twist at 2%, and Intellia at 1.14% [6] - ARK also manages the Ark Genomic Revolution Fund, which invests in companies across healthcare and information technology relevant to the genomics theme [6]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgent need for energy to support its growth [1][2][3] Group 1: AI and Energy Demand - AI technologies, particularly large language models like ChatGPT, are extremely energy-intensive, with data centers consuming as much energy as small cities [2] - The increasing demand for AI is straining global power grids, leading to rising electricity prices and a need for utilities to expand capacity [2] - Industry leaders, including Sam Altman and Elon Musk, have highlighted the critical link between AI's future and energy availability, with Musk warning of potential electricity shortages as early as next year [2] Group 2: Investment Opportunity - A specific company is positioned as a key player in the AI energy sector, owning critical energy infrastructure assets that will benefit from the anticipated surge in energy demand from AI data centers [3][7] - This company is not a chipmaker or cloud platform but is described as a "toll booth" operator in the energy market, profiting from the export of American LNG and the onshoring of manufacturing due to tariffs [5][6] - The company is debt-free and has significant cash reserves, equating to nearly one-third of its market capitalization, making it an attractive investment option [8] Group 3: Market Position and Valuation - The company is involved in large-scale engineering, procurement, and construction projects across various energy sectors, including nuclear energy, which is crucial for America's future power strategy [7] - It is trading at a low valuation of less than 7 times earnings, excluding cash and investments, indicating a potential for significant upside [10] - The company also holds a substantial equity stake in another AI-related venture, providing investors with indirect exposure to multiple growth opportunities in the AI sector [9] Group 4: Future Outlook - The ongoing AI infrastructure supercycle, combined with the onshoring boom and a surge in U.S. LNG exports, positions this company favorably for future growth [14] - The influx of talent into the AI sector ensures continuous innovation and advancements, further solidifying the importance of investing in AI-related companies [12] - The overall message emphasizes the urgency for investors to act now to capitalize on the potential for substantial returns in the AI and energy markets [15][19]

Amazon - Amazon has deployed over 1 million robots in its warehouses, projected to save up to $4 billion annually in fulfillment costs, with expectations of significantly lifting operating margins for the retail segment by 2030 [1] - The company is investing heavily in AI, with planned capital expenditures projected at $125 billion in 2025, focusing on custom silicon chips to enhance performance and reduce costs compared to competitors [2] - Amazon's advertising segment is the fastest-growing, with annualized revenue expected to exceed $60 billion in 2025, potentially approaching $100 billion annually in the coming years [3] - Amazon Web Services (AWS) remains the primary profit engine, accounting for approximately 30% of the global cloud infrastructure market [4] - In Q3 2025, Amazon reported revenue of $180.2 billion, a 13% year-over-year increase, with net income rising 38% to $21.2 billion [7] Vertex Pharmaceuticals - Vertex Pharmaceuticals has a trailing-10-year return of around 90%, driven by its cystic fibrosis drug franchise and expansion into the rare disease market [8] - The company is diversifying its portfolio with late-stage clinical programs targeting kidney disease, pain management, and type 1 diabetes, supported by a solid balance sheet and substantial free cash flow [9] - Vertex is launching Casgevy, a gene-editing therapy for sickle cell disease, and Journavx, a non-opioid medicine for pain management, with significant market interest and regulatory approvals [10][11] - The company reported revenue of over $3 billion in Q3 2025, an 11% increase from the previous year, and is positioned for significant growth through innovation and diversification [14] TJX Companies - TJX Companies has seen a nearly 150% increase in stock value over the last five years, attributed to its effective off-price retail model [15] - The company plans to expand its store footprint to 7,000 globally, enhancing its physical presence in existing and new markets [16] - TJX's business model encourages frequent shopper visits due to its ever-changing inventory and unique product offerings, appealing to cost-conscious consumers [17] - In Q3 2026, TJX reported earnings per share of $1.28 on $15.1 billion in revenue, reflecting year-over-year increases of 12% and 7% respectively [19]

Core Viewpoint - The technology sector has driven market gains this year, while the healthcare industry has lagged, although some healthcare stocks have shown strong performance [1][2]. Group 1: CRISPR Therapeutics - CRISPR Therapeutics has seen a significant rise in stock price, increasing by 44% this year, driven by clinical and regulatory progress in its pipeline [2][4]. - The company is developing CTX310, a potential one-time treatment for lowering LDL cholesterol and triglycerides, which could be a breakthrough in cardiovascular health [5][6]. - Despite being unprofitable and generating minimal revenue, CRISPR Therapeutics has potential upside due to progress in its pipeline and expectations for commercial success with its approved product, Casgevy [8][9]. Group 2: HCA Healthcare - HCA Healthcare has outperformed the market with a stock increase of 58% this year, supported by strong financial results and recognition as one of the top hospital chains [2][10]. - The company is trading at a forward price-to-earnings ratio of 16, which is below the healthcare sector average of 18.2, indicating potential value [11][12]. - There are uncertainties regarding federal policy changes that could impact patient demand for HCA's services, but the company maintains a strong competitive edge and is well-positioned for long-term growth [13][16].

Core Viewpoint - CRISPR Therapeutics has experienced significant stock volatility, with a notable decline of over 60% from its 2021 peak, despite the recent approval and commercialization of its first gene editing therapy, Casgevy, for blood disorders [2][10]. Group 1: Product Approval and Technology - Casgevy is the first CRISPR-based product approved for treating blood disorders, specifically sickle cell disease and beta thalassemia [4][7]. - The CRISPR technology utilized by the company involves precise DNA editing, which may provide a functional cure for the diseases it targets, potentially allowing patients to remain symptom-free over time [5][4]. Group 2: Financial Performance and Revenue Generation - Despite the approval of Casgevy, it has not yet generated significant revenue for CRISPR Therapeutics, as the treatment process is complex and requires establishing authorized treatment centers [7][8]. - Vertex Pharmaceuticals, a partner in the Casgevy project, anticipates that the product could generate over $100 million in revenue for the full year of 2025, but CRISPR Therapeutics will only retain 40% of the profits from this product [8][7]. Group 3: Market Sentiment and Future Outlook - The stock performance of CRISPR Therapeutics has been negatively impacted by the time it takes for revenue growth to materialize post-approval, leading some investors to view the company as "yesterday's news" [10][2]. - The company has a pipeline of other candidates based on CRISPR technology, which may also take time to deliver revenue growth and profit [9][10].

Group 1 - Cathie Wood's ARK Invest has reduced its holdings in Tesla while increasing investments in smaller, speculative stocks like Oklo, indicating a strategic shift in focus [1][5] - Oklo's stock has recently pulled back by 38% over the past three months but remains up 293% year-to-date, making it an attractive investment opportunity for ARK [2][3] - Bank of America predicts that nuclear energy could become a $10 trillion market, with global reactor capacity needing to triple by 2050, highlighting the long-term potential of companies like Oklo [3] Group 2 - The demand for continuous power is rising due to the scaling of AI computing, positioning next-generation nuclear energy as a viable solution to supplement intermittent renewable sources [4] - ARK Invest's recent trades include significant purchases of Oklo shares worth approximately $8.9 million, alongside other investments in companies like Archer Aviation and CRISPR Therapeutics [7] - The sales of Tesla and other stocks, such as Rocket Lab and Shopify, reflect a strategy of profit-taking after substantial gains, while reallocating capital towards emerging technologies [7]

Core Insights - CRISPR Therapeutics' shares increased by 3.7% following positive updates on its CAR-T therapy candidate, zugo-cel, aimed at treating autoimmune diseases and hematologic malignancies [1] Group 1: Autoimmune Disorder Studies - Zugo-cel is currently being evaluated in a phase I basket study for autoimmune rheumatologic diseases, including systemic lupus erythematosus (SLE), systemic sclerosis, and inflammatory myositis [2] - As of December 17, 2025, patients treated with zugo-cel showed deep B-cell depletion sustained for at least 28 days, with initial efficacy data indicating significant clinical improvement at the 100-million-cell dose [3] - Zugo-cel was well tolerated in the study, with no serious side effects reported, and further updates are expected in the second half of 2026 [6] Group 2: Immuno-Oncology Program - Zugo-cel is also being studied for relapsed or refractory CD19-positive B-cell malignancies, including large B-cell lymphoma (LBCL) and others [8] - The recommended phase II dose for zugo-cel was set at 600 million cells, with strong activity observed, achieving a 90% overall response rate and a 70% complete response rate in relapsed or refractory LBCL patients [10] - A collaboration with Eli Lilly has been established to evaluate zugo-cel in combination with Lilly's BTK inhibitor, Jaypirca, which was approved for treating adults with relapsed or refractory MCL in 2023 [11][12] Group 3: Market Performance - Over the past year, CRISPR Therapeutics' shares have increased by 41.5%, outperforming the industry average increase of 15.5% [4]

Tesla Trade - Ark Invest sold 60,715 shares of Tesla across multiple ETFs, with a total transaction value of approximately $29.7 million, as the stock closed at $488.73 [2] - Concerns regarding Tesla's financial prospects were raised by Gerber Kawasaki, particularly about achieving GAAP profitability, although the company's market share in the EV sector remains strong [3] Palantir Trade - Ark Invest reduced its position in Palantir by selling 47,309 shares, valued at approximately $9.2 million, with the stock closing at $193.98 [4] - BofA Securities expressed optimism about Palantir's growth, citing strong momentum in its U.S. commercial business and a recent two-year $448 million government order [5] Shopify Trade - Ark Invest sold 33,164 shares of Shopify, valued at approximately $5.6 million, with a closing price of $169.67 [6] - Shopify's recent Winter 2026 Edition showcased expanded capabilities in AI and merchant tools, reinforcing confidence in its long-term growth according to JPMorgan [7] WeRide Trade - Ark Invest purchased 520,697 shares of WeRide, valued at approximately $4.7 million, with the stock closing at $8.97 [8] - WeRide launched public Robotaxi rides in Dubai, marking progress towards a fully driverless rollout planned for early 2026 [9] Other Key Trades - Ark Invest acquired 78,793 shares of CRISPR Therapeutics across ARKG and ARKK [10] - Intellia Therapeutics saw an acquisition of 187,880 shares via ARKG and ARKK, while Rocket Lab sold 232,425 shares through ARKQ and ARKX [12]

Core Insights - CRISPR Therapeutics AG provided updates on its investigational allogeneic CAR T therapy, zugocaptagene geleucel (zugo-cel), targeting CD19 for autoimmune diseases and hematologic malignancies [1] Autoimmune Disease - Zugo-cel is currently in a Phase 1 basket trial for autoimmune rheumatologic diseases, with preliminary clinical data showing encouraging results and good tolerability [2] - As of December 17, four patients received a dose of 100 million cells, showing comparable cell expansion to that in B-cell lymphoma trials [3] - Rapid and deep B-cell depletion was observed within 1-2 days, maintained over the first month, with all patients showing significant clinical improvement by Day 28 [4] - No high-grade cytokine release syndrome (CRS) or immune-effector cell-associated neurotoxicity syndrome (ICANS) was reported, and ongoing trials are expected to provide updates in the second half of 2026 [5] Immuno-Oncology - Zugo-cel was administered after lymphodepletion with fludarabine and cyclophosphamide, with 39 patients treated across four dose levels [6] - At the recommended Phase 2 dose of 600 million cells, 10 patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) showed an overall response rate of 90% and a complete response rate of 70% [7] - Among patients with 12 months of follow-up, 67% remained in complete response, with peak CAR T cell expansion observed at approximately 1,700 cells/µL, a four-fold increase compared to the 300 million cell dose [8] - No Grade 3 ICANS or CRS was observed at the 100 million cell dose currently being studied in autoimmune trials [9] - The Phase 1/2 trial in R/R B-cell malignancies is ongoing, with additional updates expected in the second half of 2026, and a new collaboration with Eli Lilly has been established to evaluate zugo-cel with pirtobrutinib in aggressive B-cell lymphomas [10] Market Reaction - CRISPR Therapeutics shares increased by 3.46% to $57.79 at the time of publication [11]

Core Insights - CRISPR Therapeutics has provided updates on zugocaptagene geleucel (zugo-cel), an investigational allogeneic CAR T therapy targeting CD19, showing promising results in both autoimmune diseases and hematologic malignancies [1][9] Autoimmune Disease - Zugo-cel is currently in a Phase 1 basket trial for autoimmune rheumatologic diseases, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory myositis, with preliminary data indicating it has been well tolerated [3][4] - Four patients treated at a dose of 100 million cells showed deep B-cell depletion sustained for at least 28 days, with significant clinical improvement observed by Day 28 [4] - The first SLE patient, refractory to nine prior therapies, achieved DORIS remission through Month 6 post-treatment [4] Hematologic Malignancies - In a separate Phase 1/2 trial for relapsed or refractory (R/R) B-cell malignancies, zugo-cel demonstrated an overall response rate (ORR) of 90% and a complete response rate (CRR) of 70% at the 600 million cell dose [11] - The recommended Phase 2 dose (RP2D) for large B-cell lymphoma (LBCL) has been established at 600 million cells, with 39 patients treated across all dose levels [7][11] - A collaboration with Lilly has been initiated to evaluate zugo-cel in combination with pirtobrutinib for aggressive B-cell lymphomas, expanding the program's development [1][8] Future Developments - Additional updates across autoimmune diseases and hematological malignancies are expected in the second half of 2026, with ongoing clinical trials in immune thrombocytopenic purpura (ITP) and warm autoimmune hemolytic anemia (wAIHA) [5][8]